VGX Pharmaceuticals Receives FDA Approval of IND for Novel DNA Vaccine for Cervical Cancer Therapy
Posted on: Tuesday, 1 July 2008, 12:01 CDT
VGX Pharmaceuticals, Inc. (VGX) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available at http://www.clinicaltrials.gov/ct2/show/NCT00685412?term=vgx&rank=1
VGX-3100 is the first of the Company's several proprietary SynCon(TM) DNA vaccine candidates delivered by its CELLECTRA(R) electroporation device planned to enter Phase I clinical testing. The SynCon(TM) DNA vaccines in combination with the CELLECTRA(R) delivery device provide greater levels of cross-reactive immune responses than those produced by more traditional vaccines.
"We are pleased with the FDA's acceptance of our VGX-3100 IND application for treating cervical cancer," stated Dr. J. Joseph Kim, President and Chief Executive Officer. "This accomplishment further demonstrates the potential and efficiency of our DNA-based product development platform."
VGX-3100 is a DNA-based therapeutic vaccine that has the potential to treat cervical cancer caused by the human papilloma virus (HPV). VGX-3100 utilizes synthetic consensus sequences based on HPV antigens that offer coverage across different viral sub-types (types 16 and 18), which could potentially treat 71% of all cervical cancers. Prophylactic vaccines for HPV, including Merck's Gardasil(R) and GSK's Cervarix(TM) have been recently approved and are helping to prevent HPV infection. There is still an unmet need for treating individuals who have previously been exposed to HPV.
About VGX Pharmaceuticals
More information about VGX can be found at www.vgxp.com.
Source: Business Wire
Related Articles
- Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
- GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
- VGX Pharmaceuticals Announces Filings of Two Separate INDs Covering Novel DNA Vaccines: One for Cervical Cancer Therapy (VGX-3100) and One for Avian Influenza (VGX-3400)
- Robust New Technology Platforms Aid the Search for Cancer Vaccines
- Cancer Vaccines Are the Newest Weapon in the Battle Against Cancer
- Cervical-Cancer Vaccines' Makers Argue Over Study
- Experimental Cervical Cancer Vaccine Shows Promise
- Merck's Investigational Vaccine GARDASIL(TM) Prevented 100 Percent of Cervical Pre-Cancers and Non-Invasive Cervical Cancers Associated With HPV Types 16 and 18 in New Clinical Study
- Advaxis' Listeria Cancer Vaccine Shows Strong Safety Profile In Toxicology Studies
- Cancer Vaccine; Cancer vaccines use high molecular weight stress proteins
 |
 |
User Comments (0)
RSS Feeds